NB005

NB005 blocking antibody should enhance effector CD8 T-cell function by “releasing the break” leading to more efficient tumor cell killing as a stand-alone function or in combination with existing ICBs (ex: PD-1).

NB005 is an innovative humanized monoclonal antibody that has been specifically designed to interact with a novel immune checkpoint (IC) modulator found on T-cells, aiming to augment their effector function. The ligand responsible for activating this receptor is expressed on multiple solid tumor types. Importantly, this IC receptor is upregulated on T-cells within the tumor microenvironment (TME) of patients who have shown resistance to PD-1 treatment. Translational studies conducted on human primary cells have confirmed the functionality of this IC receptor, exhibiting enhanced production of IFNγ (interferon-gamma).

Our belief is that NB005 holds great potential as a standalone therapeutic option and also has the capability to complement existing market therapies such as PD-1/PD-L1/CTLA-4 in combination therapy. By leveraging the unique properties of NB005, we aim to enhance the efficacy and broaden the scope of current treatment approaches available to the patients.

Click to expand